Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC10A1 | Q14973 | 9/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21869116 | 0.99 | NPSR1 (0.50) | NPSR1MAPK1MAPTNPC1RAB9A | |
| SCHEMBL21868869 | 0.96 | NPSR1 (0.46) | NPSR1MAPK1MAPTNPC1RAB9A | |
| SCHEMBL19900989 | 0.83 | SLC10A1 (0.50) | NPSR1MAPTSLC10A1 | |
| SCHEMBL19900868 | 0.79 | SLC10A1 (0.54) | NPSR1MAPTLMNASLC10A1 | |
| SCHEMBL21868924 | 0.78 | ENPP2 (0.44) | NPSR1MAPK1MAPTNPC1RAB9A | |
| SCHEMBL22646427 | 0.78 | SLC10A1 (0.34) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL22646289 | 0.77 | POLB (0.36) | MAPTNPC1RAB9AALDH1A1PKM | |
| SCHEMBL21868898 | 0.76 | SLC10A1 (0.47) | MAPK1SLC10A1 | |
| SCHEMBL21869085 | 0.75 | ENPP2 (0.45) | NPSR1MAPK1MAPTNPC1RAB9A | |
| SCHEMBL21868856 | 0.75 | RAB9A (0.44) | NPSR1MAPK1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| EP-3628674-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | Shanghai Longwood Biopharmaceuticals Co., Ltd. (CN) | 2020-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591334-B2 | Substituted pyrrolizines for the treatment of hepatitis B | SLC10A1, NUP188, NR1H4 | NPSR1 2156/4885MAPK1 1633/4885MAPT 31/4885 |
| US-20200354366-A1 | BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B | SLC10A1, NR1H4, NUP188 | NPSR1 3668/4885MAPK1 2842/4885MAPT 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.